Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.
Why Is Agenus (AGEN) Stock Down 55% Today?
Agenus (NASDAQ: AGEN ) stock is falling hard on Thursday after the clinical-stage biotechnology company provided results from a Phase 2 clinical trial of botensilimab and balstilimab as a colorectal cancer treatment. Specfically, the company met with the Food and Drug Administration (FDA) to conduct an end-of-Phase 2 meeting.
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small- and mid-cap stocks are known to be highly sensitive to interest rates. With the Federal Reserve expected to start cutting rates no later than 2025, these equities may be on the verge of a turnaround.
